Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 3/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 9/20 | 0.43 |
| ▸ | HTT | P42858 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23355058 | 0.79 | GPR6 (0.48) | LMNAHTTKMT2AALDH1A1MAPT | |
| SCHEMBL21244030 | 0.77 | MAPT (0.55) | LMNAHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL21244041 | 0.77 | TSHR (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21244026 | 0.77 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24628362 | 0.75 | LMNA (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21244042 | 0.75 | ALDH1A1 (0.52) | LMNAHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL29772887 | 0.75 | LMNA (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24628363 | 0.73 | LMNA (0.44) | LMNAHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL29772850 | 0.73 | LMNA (0.44) | LMNAHTTKMT2AALDH1A1MEN1 | |
| SCHEMBL23536417 | 0.72 | SMN1; SMN2 (0.56) | LMNAHTTKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | Lysoway Therapeutics, Inc. (US) | 2020-12-01 | — | — | US | claimed |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | CalyGene Biotechnolgy, Inc. (US) | 2019-08-15 | — | — | US | claimed |
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | Lysoway Therapeutics, Inc. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | Lysoway Therapeutics, Inc. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | CalyGene Biotechnolgy, Inc. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | CalyGene Biotechnolgy, Inc. (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851084-B2 | Piperazine derivatives as TRPML modulators | TRPM5, TRPM2, TRPM4 | C5AR1 4777/4885PSEN1 67/4885PSEN2 66/4885 |
| US-20190248764-A1 | PIPERAZINE DERIVATIVES AS TRPML MODULATORS | TRPM5, TRPM2, TRPM4 | C5AR1 4777/4885PSEN1 67/4885PSEN2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.